Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
Never, ever leave it at room temperature for any extended period
Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials
Body Measurements, National Center for Health Statistics, CDC, accessed April 20, 2025, [70]
In a recent overview of GLP-1-based therapeutics, Drucker highlighted that newer agents are producing greater and more rapid weight loss, may have important implications for musculoskeletal health, and are now being studied across indications extending beyond diabetes and obesity alone (Drucker, 2025)
While more research is needed to confirm these findings in humans, they suggest that semaglutide may have potential as a treatment for GI inflammation